In all groups, most T2DM subjects were administered lipid lowering agents: GC (85.2%), GCC (93.8%), PC (61.9%) and PCC (87.5%) and also administered angiotensin converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) in view of HTN or micro/macro albuminuria: GC (74.1%), GCC (87.5%), PC (76.2%), and PCC (81.3%) (Table 2). This evidence concerns the gene ACE and hypertensive disorder.